RUBYnanomed
Description
RUBYnananomed provides non-invasive monitoring of cancer progression.
Areas / Lines R+D+i
- In vitro diagnostics
- Accompanying Diagnosis
- Precision oncology
- Rare cell isolation and analysis
- Cancer Biomarkers
Most important R+D+i projects
- Resolve: Her2 expression in CTCs of patients with metastatic breast cancer
- OncoDynamicsBiobanking: understanding the role of EMT CTCs in the progression and therapeutic resistance in metastatic breast, prostate, colorectal and melanoma cancer
- Expression of NTS in early and metastatic cancers of the digestive system
- Presence of CTCs in patients with early breast cancer
- Role of NTS in the aggressiveness and prevalence of bladder cancer
Contact
Email: lorena.dieguez@rubynanomed.com innovation@rubynanomed.com
Others
Startups
Join us!
Do you want to appear on the platform? If you are part of the biotechnological sector of the Euroregion Galicia – North of Portugal, sign up!